Therapy Settings Associated with Optimal Outcomes for t:slim X2 with Control-IQ Technology in Real-World Clinical Care

67% of people using Control-IQ technology have less aggressive settings than the AACE guidelines (100/TDI). The Correction Factor is a unique parameter with CIQ, that affects user boluses, the autocorrection bolus, and the intensity of basal modulation. For Control-IQ users, strengthening the Correction Factor may improve TIR without necessarily impacting hypoglycaemia. Both C:I ratio and basal rate changes can be considered as well, although may predict more hypoglycaemia.

https://www.liebertpub.com/doi/10.1089/dia.2023.0308